<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467373</url>
  </required_header>
  <id_info>
    <org_study_id>NP40126</org_study_id>
    <secondary_id>2017-003648-18</secondary_id>
    <nct_id>NCT03467373</nct_id>
  </id_info>
  <brief_title>A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL</brief_title>
  <official_title>A Phase 1B Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1B, multi-center, dose-finding study of glofitamab administered in&#xD;
      combination with obinutuzumab (Gazyva; [G]), rituximab (R) and standard doses of CHOP&#xD;
      (G/R-CHOP or R-CHOP) in participants with r/r NHL and untreated diffuse large B-cell lymphoma&#xD;
      (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and&#xD;
      pharmacodynamic effects of this combination will be the main objectives of this study. The&#xD;
      study is divided in two parts:&#xD;
&#xD;
        -  Part I: Dose finding in participants with r/r NHL; test use of G vs R in Cycle 1&#xD;
&#xD;
        -  Part II: Dose Expansion. The maximum tolerated dose or optimal biological dose (MTD or&#xD;
           OBD) will be further assessed in participants with r/r NHL and those with untreated&#xD;
           DLBCL (&gt;60 years of age with an age-adjusted International Prognostic Index (IPI) of&#xD;
           2-3). Particularly, the impact of using glofitamab plus G/R-CHOP (i.e., add-on arm)&#xD;
           versus glofitamab plus CHOP (i.e., replacement arm) will be assessed in untreated DLBCL&#xD;
           participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">December 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 16, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Percentage of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 29 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I and II: Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to 29 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Percentage of Participants with a Complete Response (CR) as Assessed by the Investigator using Modified Lugano 2014 Criteria</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Percentage of Participants with Overall Response (Partial Response [PR] or Complete Response [CR])</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Duration of Response (DOR)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Complete Response (TFCR)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response (TFOR)</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Area Under the Serum Concentration Versus Time Curve (AUC) of Glofitamab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Time to Maximum Serum Concentration (tmax) of Glofitamab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Maximum Serum Concentration (Cmax) of Glofitamab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts I and II: Minimum Serum Concentration (Cmin) of Glofitamab</measure>
    <time_frame>Cycle 1 Day 1 up to 29 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in T-cell Activation Markers</measure>
    <time_frame>Up to 29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>B-Cell Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding in participants with r/r NHL: the study will explore different doses of glofitamab in the induction period, starting at a dose of 70 mcg administered in combination with standard of care doses of G/R CHOP and R-CHOP every 3 weeks (Q3W). Participants with r/r NHL will receive 6 cycles of induction treatment (G/R-CHOP). Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) at the end of induction (EOInd) may optionally receive post-induction treatment (referred to as maintenance) with glofitamab alone.&#xD;
The use of G versus R in Cycle 1 will be compared in parallel dose escalation cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with r/r NHL will be assigned to an expansion cohort to further explore glofitamab at the MTD/OBD determined in Part I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glofitamab</intervention_name>
    <description>Glofitamab will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <other_name>RO7082859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab (G)</intervention_name>
    <description>Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab (R)</intervention_name>
    <description>Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle</description>
    <arm_group_label>Part 1: Dose Escalation r/r NHL</arm_group_label>
    <arm_group_label>Part 2: DLBCL CHOP</arm_group_label>
    <arm_group_label>Part 2: DLBCL G/R-CHOP</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion r/r NHL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;/=18 years&#xD;
&#xD;
          -  For Part I r/r NHL dose-escalation, and Part II r/r NHL expansion:&#xD;
             Histologically-confirmed NHL that is expected to express CD20, and which has&#xD;
             relapsed/progressed following at least one prior treatment regimen containing R or G.&#xD;
             Participants must be appropriate for treatment with CHOP and typically should not have&#xD;
             been exposed to prior anthracyclines or must not exceed the cumulative lifetime dose&#xD;
             of anthracyclines&#xD;
&#xD;
          -  For Part II untreated DLBCL expansion: Histologically confirmed previously-untreated&#xD;
             DLBCL that is expected to express CD20&#xD;
&#xD;
          -  Able to provide a pretreatment biopsy between the last dose of last prior therapy and&#xD;
             initiation of study medication at Cycle 1/Day 1&#xD;
&#xD;
          -  Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion,&#xD;
             defined as &gt;1.5 cm in its longest dimension, or at least one bi-dimensionally&#xD;
             measurable extranodal lesion, defined as &gt;1.0 cm in its longest dimension.&#xD;
&#xD;
          -  Participants must have at least one measurable target lesion (&gt; or = 1.5 cm) in its&#xD;
             largest dimension by computed tomography (CT) scan&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 for&#xD;
             participants with r/r NHL; ECOG performance status 0-3 for participants with untreated&#xD;
             DLBCL&#xD;
&#xD;
          -  Life expectancy (in the opinion of the Investigator) of 18 weeks&#xD;
&#xD;
          -  Adverse events (AEs) from prior anti-cancer therapy must have resolved to Grade &lt; or =&#xD;
             1&#xD;
&#xD;
          -  Adequate liver function&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Negative serologic or polymerase chain reaction (PCR) test results for acute or&#xD;
             chronic hepatitis B virus (HBV) infection&#xD;
&#xD;
          -  Negative test results for hepatitis C virus (HCV) and human immunodeficiency virus&#xD;
             (HIV)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with protocol mandated hospitalization and restrictions&#xD;
&#xD;
          -  Participants with known active infection, or reactivation of a latent infection,&#xD;
             whether bacterial, viral (including, but not limited to Epstein Barr virus (EBV),&#xD;
             cytomegalovirus (CMV), HBV, HCV, and HIV), fungal, mycobacterial, or other pathogens&#xD;
             (excluding fungal infections of nail beds) or any major episode of infection requiring&#xD;
             hospitalization or treatment with IV antibiotics (for IV antibiotics, this pertains to&#xD;
             completion of last course of antibiotic treatment) within 4 weeks of dosing&#xD;
&#xD;
          -  Prior treatment with systemic immunotherapeutic agents, including, but not limited to,&#xD;
             radioimmuno-conjugates, antibody-drug conjugates, immune/cytokines, and monoclonal&#xD;
             antibodies (e.g., anti-CTLA4, anti-PD1, and anti-PDL1) within 4 weeks or five&#xD;
             half-lives of the drug, whichever is shorter, before G- or R-CHOP infusion on Cycle&#xD;
             1/Day 1&#xD;
&#xD;
          -  History of treatment-emergent immune-related AEs associated with prior&#xD;
             immunotherapeutic agents, as follows: Grade &gt;/=3 AEs, with the exception of Grade 3&#xD;
             endocrinopathy managed with replacement therapy; Grade 1-2 AEs that did not resolve to&#xD;
             baseline after treatment completion&#xD;
&#xD;
          -  Contraindication to any of the individual components of the chemotherapy&#xD;
&#xD;
          -  Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with&#xD;
             any other investigational anti-cancer agent within 4 weeks prior to study treatment at&#xD;
             Cycle 1/Day 1 infusion&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  Autologous stem cell transplantation within 100 days prior to Cycle 1/Day 1&#xD;
&#xD;
          -  Prior treatment with CAR T-cell therapy within 30 days prior to study treatment at&#xD;
             Cycle 1 Day 1&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibody therapy (or recombinant antibody-related fusion proteins)&#xD;
&#xD;
          -  A history of confirmed progressive multifocal leukoencephalopathy&#xD;
&#xD;
          -  Current or past history of central nervous system (CNS) lymphoma&#xD;
&#xD;
          -  Ongoing corticosteroid use &gt; 30 mg/day of prednisone or equivalent. Participants who&#xD;
             received corticosteroid treatment with &lt;/=30 mg/day of prednisone or equivalent must&#xD;
             be documented to be on a stable dose of at least 4 weeks' duration prior to Cycle&#xD;
             1/Day 1. Participants may have received a brief (&lt;7 days) course of systemic steroids&#xD;
             (&lt;/=100 mg prednisone equivalent per day) prior to initiation of study therapy for&#xD;
             control of lymphoma-related symptoms&#xD;
&#xD;
          -  Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or&#xD;
             neurodegenerative disease&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results, including diabetes&#xD;
             mellitus, history of relevant pulmonary disorders (bronchospasm, obstructive pulmonary&#xD;
             disease), and known autoimmune diseases&#xD;
&#xD;
          -  Major surgery or significant traumatic injury &lt; 28 days prior to the study treatment&#xD;
             infusion at Cycle 1/Day 1 (excluding biopsies) or anticipation of the need for major&#xD;
             surgery during study treatment&#xD;
&#xD;
          -  Participants with another invasive malignancy that could affect compliance with the&#xD;
             protocol or interpretation of results&#xD;
&#xD;
          -  Significant or extensive cardiovascular disease&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before study treatment&#xD;
             infusion on Cycle 1 Day 1 or anticipation that such a live, attenuated vaccine will be&#xD;
             required during the study&#xD;
&#xD;
          -  History of illicit drug or alcohol abuse within 12 months prior to screening, in the&#xD;
             Investigator's judgment&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding (including&#xD;
             mental status), or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition that would contraindicate the use of an investigational drug&#xD;
&#xD;
          -  Participants with latent or active tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID: NP40126 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Inst</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase-Temple Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University; Health Sciences Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute; Clinical Trials</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet; Hæmatologisk Klinik</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Hematologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu Et Hme; Clinique Hematologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel; Hematologie</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Translational Research Center (TRC), Medizin 5</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UO Ematologia, Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>Emilia-Romagna</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII; Ematologia</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The HOPE Clinical Trials Unit</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust; NIHR UCLH Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital; Haematology</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

